Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation
The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Massachusetts General Hospital.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Massachusetts General Hospital
Information provided by:
Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00981760
First received: September 18, 2009
Last updated: May 3, 2010
Last verified: May 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
One risk of a stem cell transplant is that the donated stem cells do not grow in the recipient. This is called graft rejection. Previous laboratory research has suggested that the reaction between the recipient's cells and the donor's cells that causes graft rejection is associated with an anti-cancer effect. In this research study the investigators will give participants some of their own white blood cells after their transplant. This is called a recipient leukocyte infusion (RLI). This is done to cause the participant's immune system to react against the donor's cells and reject the transplant. The purpose of this research study is to learn if the graft rejection has an anti-cancer effect.
| Condition | Intervention | Phase |
|---|---|---|
|
Non-Hodgkin's Lymphoma Hodgkin's Lymphoma Multiple Myeloma |
Radiation: Total Body Irradiation Drug: Fludarabine Procedure: Recipient Leukocyte Infusion |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation |
Resource links provided by NLM:
Further study details as provided by Massachusetts General Hospital:
Primary Outcome Measures:
- To develop a conditioning regimen achieving initial mixed chimerism of HLA-mismatched related donor CD34+ cells without GVHD [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- To determine the safety including acute GVHD and transplant related mortality at <100 days of this regimen when followed by infusion of RLI to induce deliberate rejection of donor graft [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Evaluate the incidence of acute and chronic GVHD [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Evaluate the incidence of loss of donor grafts [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- To evaluate progression-free and overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- To evaluate anti-tumor responses following this transplant strategy [ Time Frame: 2 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 20 |
| Study Start Date: | July 2008 |
| Estimated Study Completion Date: | June 2010 |
| Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Group 1
Conditioning regimen of total body irradiation (TBI) before the stem cell transplant
|
Radiation: Total Body Irradiation
One low-dose total body irradiation 4-6 hours before the infusion of donor's stem cells.
Other Name: TBI
Procedure: Recipient Leukocyte Infusion
Infusion of participant's white blood cells given 5 weeks after the stem cell transplant if there is evidence of the stem cell graft having partially taken and no evidence of GVHD
Other Name: RLI
|
|
Experimental: Group 2
Receive fludarabine for three days before the TBI
|
Radiation: Total Body Irradiation
One low-dose total body irradiation 4-6 hours before the infusion of donor's stem cells.
Other Name: TBI
Drug: Fludarabine
Given intravenously over 30 minutes for three days. Last dose given two days before TBI.
Procedure: Recipient Leukocyte Infusion
Infusion of participant's white blood cells given 5 weeks after the stem cell transplant if there is evidence of the stem cell graft having partially taken and no evidence of GVHD
Other Name: RLI
|
Detailed Description:
- The first 10 participants (Group 1) will receive a conditioning regimen of total body irradiation (TBI) before the stem cell transplant. It is possible this conditioning regimen may suppress the immune system enough. This can cause the stem cell transplant to be rejected to quickly. It is necessary for the transplant to begin to grow before it is rejected. If the participants in Group 1 reject their stem cell transplant too quickly, the next group of 10 participants (Group 2) will receive a medication called fludarabine for three days before the TBI. The purpose of adding fludarabine is to suppress the immune system enough to allow the transplant to initially grow. An additional RLI may be given 2 weeks after the first RLI.
- Before the conditioning regimen (either TBI or fludarabine), participants will undergo a procedure to collect their white blood cells called leukapheresis. The white blood cells collected will then be frozen and stored and given to the participant as an RLI on Day 38 after their stem cell transplant.
- Participants will receive their donor's stem cells about 4-6 hours after TBI. They will also receive the following medications to prevent GVHD: Cyclosporine orally until about day 35 and Mycophenolate Mofetil (MMF) orally until 21 days after the stem cell transplant.
Eligibility| Ages Eligible for Study: | 18 Years to 74 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Chemorefractory non-Hodgkin's or Hodgkin's lymphoma or multiple myeloma
- Estimated disease-free survival of less than one year
- 18-74 years of age
- ECOG Performance Status of 0,1 or 2
Exclusion Criteria:
- Patients whose life expectancy is limited by diseases other than their malignancy
- Patients who have a 5/6 or better matched related donor or a 4/6 or better umbilical cord blood donor and who are medically eligible for conventional myeloablative or non-myeloablative transplant
- Cardiac disease: symptomatic congestive heart failure or RVG or echocardiogram determined left ventricular ejection fraction of <30%, active angina pectoris, or uncontrolled hypertension
- Pulmonary disease: severe chronic obstructive lung disease, or symptomatic restrictive lung disease, or corrected DLCO of <40% of predicted
- Renal disease: serum creatinine > 3.0mg/dl
- Hepatic disease: serum bilirubin > 3.0mg/dl or alkaline phosphatase, SGOT or SGPT >3x normal
- Neurologic disease: symptomatic leukoencephalopathy, active CNS malignancy or other neuropsychiatric abnormalities believed to preclude transplantation
- Uncontrolled infection
- RLI might involve the infusion of circulating tumor cells to the patients. To minimize the risk, patients who have evidence of circulating tumor cells by light microscopy and flow cytometry will be excluded
- Patients with acute leukemia
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00981760
Contacts
| Contact: Bimal Dey, MD | 617-724-1124 | |
| Contact: Amy Karr | 617-726-1456 |
Locations
| United States, Massachusetts | |
| Massachusetts General Hospital | Recruiting |
| Boston, Massachusetts, United States, 02214 | |
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
| Principal Investigator: | Bimal Dey, MD | Massachuestts General Hospital |
More Information
No publications provided
| Responsible Party: | Bimal Dey, MD, Massachusetts General Hospital |
| ClinicalTrials.gov Identifier: | NCT00981760 History of Changes |
| Other Study ID Numbers: | 07-068 |
| Study First Received: | September 18, 2009 |
| Last Updated: | May 3, 2010 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Massachusetts General Hospital:
|
RLI stem cell transplantation fludarabine |
Additional relevant MeSH terms:
|
Hodgkin Disease Lymphoma Lymphoma, Non-Hodgkin Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias |
Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Fludarabine Fludarabine monophosphate Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 16, 2013